Last reviewed · How we verify
ECC4703
ECC4703 is a small molecule targeting the SGLT2 receptor.
ECC4703 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | ECC4703 |
|---|---|
| Sponsor | Eccogene |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
SGLT2 inhibitors like ECC4703 work by blocking the reabsorption of glucose in the kidneys, leading to reduced blood glucose levels. This can be beneficial for patients with type 2 diabetes. ECC4703 is being investigated for its potential to improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) (PHASE2)
- ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants (PHASE1)
- FTIH of ECC4703 in Healthy Volunteers (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ECC4703 CI brief — competitive landscape report
- ECC4703 updates RSS · CI watch RSS
- Eccogene portfolio CI